Categories: Prescription Medication
Description:
Docetaxel is a key treatment for metastatic castration-resistant prostate cancer (mCRPC) and was the first therapy shown to improve overall survival in this setting. It is typically used after the disease progresses despite androgen deprivation therapy (ADT), often in patients who have already tried oral androgen receptor pathway inhibitors like enzalutamide or abiraterone.
Docetaxel is given as an intravenous infusion, usually every 3 weeks for up to 10 cycles, and works by interfering with cancer cell division. It's most appropriate for patients with rapidly progressing disease, high symptom burden, or visceral metastases. Common side effects include fatigue, low blood counts, hair loss, neuropathy, and increased infection risk, so it's best suited for patients with good performance status.
Treatment For:
AI generated Summary: Based on the provided information, there are no user reviews or ratings available for the treatment 'Docetaxel' against 'Prostate Cancer, Metastatic Castration-Resistant'. The author has not provided any review or rating either. Therefore, it is not possible to determine the effectiveness of this treatment without further data or evidence.
The information, including but not limited to, text, graphics, images and other material contained on this website/app are for informational purposes only. No material on this site/app is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website/app.
Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.
